An elevated number of eosinophils have been implicated in several type 2 inflammatory chronic diseases that occur at various sites in the body. Over the past 20 years, our knowledge of diseases associated with increased numbers of eosinophils has advanced thanks to the development of drugs that can reduce or even eliminate eosinophils. One such agent is mepolizumab, a humanized monoclonal antibody that binds to interleukin -5 (IL-5). This article briefly and clearly summarizes the pharmacological profile of mepolizumab and its current indications for a number of chronic eosinophilic diseases.
Keywords: chronic rhinosinusitis with nasal polyps (CRSwNP); eosinophilic granulomatosis with polyangiitis (EGPA); hypereosinophilic syndrome (HES).; mepolizumab; severe eosinophilic asthma (SEA).